Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
RVTY - Revvity, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$124.00
DETAILS
HIGH:
$165.00
LOW:
$95.00
MEDIAN:
$121.00
CONSENSUS:
$124.00
UPSIDE:
2.42%
Stock News
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
What Makes Revvity (RVTY) a New Buy Stock
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bank of New York Mellon Corp Invests $78.77 Million in Revvity Inc. $RVTY
Bank of New York Mellon Corp purchased a new stake in Revvity Inc. (NYSE: RVTY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 707,941 shares of the company's stock, valued at approximately $78,766,000. Bank of New York Mellon Corp
Is the Options Market Predicting a Spike in Revvity Stock?
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors
On August 19, 2026, Revvity Inc (RVTY) shares rose by 5.0% to a current price of $119.45, moving within a 52-week range of $81.22 to $122.11. This upward moveme
Assenagon Asset Management S.A. Has $1.72 Million Stock Position in Revvity Inc. $RVTY
Assenagon Asset Management S.A. lessened its stake in Revvity Inc. (NYSE: RVTY) by 35.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,483 shares of the company's stock after selling 8,540 shares during the quarter. Assenagon Asset Management
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Revvity Inc. $RVTY Shares Acquired by Cetera Investment Advisers
Cetera Investment Advisers raised its position in Revvity Inc. (NYSE: RVTY) by 59.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,554 shares of the company's stock after purchasing an additional 5,445 shares during the period. Cetera
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird's 2026 Global Healthcare Conference Tuesday, September.
Revvity to Present at Upcoming Investor Conferences
[url="]Revvity, Inc.[/url] (NYSE: RVTY), today announced it will present at the following investor conferences:Wells Fargo 21st Annual Healthcare ConferenceWedn
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an.
Revvity Q2 Earnings Call Highlights
Revvity NYSE: RVTY reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows.
RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up
Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.
Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript
Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Medical equipment maker Revvity raised its annual profit and revenue forecasts on Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-development tools and diagnostic testing products.
Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates
Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago.
Is Revvity Inc (RVTY) Undervalued? Q2 Earnings Report Shows GAAP EPS at $0.48 and Revenue Reaches $730 Million -- GF Score 75/100
Revvity Inc (RVTY) released its 8-K filing detailing its earnings for the second quarter of 2026 on August 4, 2026. The company reported notable increases in re
Price Targets
Revvity assumed with a Neutral at UBS
$140.00
(was $127.08)
UBS
Revvity price target raised to $165 from $125 at KeyBanc
$165.00
(was $130.63)
KeyBanc
RBC Capital Starts Revvity Inc (RVTY) at Sector Perform
$135.00
(was $128.67)
Dan Leonard
·
RBC Capital
Revvity price target raised to $125 from $110 at Evercore ISI
$125.00
(was $111.66)
Vijay Kumar
·
Evercore ISI
Revvity resumed with a Market Perform at Bernstein
$115.00
(was $113.53)
Bernstein
Revvity price target lowered to $100 from $110 at Stifel
$100.00
(was $92.30)
Stifel Nicolaus
Revvity price target lowered to $117 from $125 at Baird
$117.00
(was $92.30)
Catherine Ramsey Schulte
·
Robert W. Baird
Revvity price target lowered to $125 from $129 at Baird
$125.00
(was $86.68)
Robert W. Baird
Revvity downgraded to Equal Weight from Overweight at Barclays
$95.00
(was $92.64)
Luke Sergott
·
Barclays
Revvity price target raised to $129 from $123 at Baird
$129.00
(was $103.89)
Catherine Ramsey Schulte
·
Robert W. Baird
Revvity price target raised to $124 from $120 at TD Cowen
$124.00
(was $106.97)
Cowen & Co.
Revvity price target raised to $118 from $112 at Evercore ISI
$118.00
(was $107.09)
Evercore ISI
Revvity price target raised to $118 from $115 at Barclays
$118.00
(was $107.09)
Barclays
Revvity price target raised to $105 from $100 at Jefferies
$105.00
(was $107.05)
Jefferies
Revvity price target raised to $107 from $102 at Wells Fargo
$107.00
(was $100.46)
Brandon Couillard
·
Wells Fargo
Revvity price target raised to $115 from $105 at Barclays
$115.00
(was $100.46)
Luke Sergott
·
Barclays
Revvity initiated with a Neutral at Goldman Sachs
$105.00
(was $99.79)
Evie Koslosky
·
Goldman Sachs
Revvity price target raised to $123 from $122 at Baird
$123.00
(was $97.73)
Robert W. Baird
Revvity price target raised to $105 from $100 at Barclays
$105.00
(was $97.16)
Barclays
Revvity price target raised to $108 from $106 at Evercore ISI
$108.00
(was $95.89)
Evercore ISI